Cassava Sciences Faces Multiple Class Action Lawsuits Over Alleged Misconduct

Investors claim false statements about drug research and data management led to financial losses.

Investors of Cassava Sciences, Inc. are encouraged to join class action lawsuits due to alleged false and misleading statements about the company's operations and drug research programs.
The lawsuits cover a class period from August 18, 2022, to October 12, 2023, with a lead plaintiff deadline set for April 2, 2024.
Claims include failure to maintain effective data management controls, resulting in data manipulation to overstate the effectiveness of simufilam, Cassava's lead therapeutic drug candidate.
Rosen Law Firm and Bronstein, Gewirtz & Grossman, LLC, among others, are leading the legal actions, citing significant potential financial and reputational harm to the company.
The allegations were exacerbated by a report on possible data manipulation involving a researcher associated with simufilam's research program, leading to a significant drop in Cassava's stock price.